PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+11.58%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$3.59B
AUM Growth
+$3.59B
(-23%)
Cap. Flow
-$646M
Cap. Flow
% of AUM
-18%
Top 10 Holdings %
Top 10 Hldgs %
50.81%
Holding
126
New
21
Increased
12
Reduced
43
Closed
26
Top Buys
| 1 |
Janux Therapeutics
JANX
|
$43.8M |
| 2 |
Insulet
PODD
|
$23.5M |
| 3 |
Inhibikase Therapeutics
IKT
|
$19.3M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$17.6M |
| 5 |
Penumbra
PEN
|
$17.4M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$76.6M |
| 2 |
Biohaven
BHVN
|
$74.2M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
$61.4M |
| 4 |
Apogee Therapeutics
APGE
|
$43.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$35.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Dyne Therapeutics
DYN
$1.92B
| $12.8M | 0.35% |
543,277
-174,867
| -24% | -$4.12M |
|
52
Xenon Pharmaceuticals
XENE
$2.99B
| $12.8M | 0.35% |
325,324
-199,606
| -38% | -$7.82M |
|
53
Merus
MRUS
$5.04B
| $12.6M | 0.35% |
300,000
| – | – |
|
54
CG Oncology
CGON
$2.19B
| $12M | 0.33% |
419,450
-314,245
| -43% | -$9.01M |
|
|
AVR
55
Anteris Technologies Global Corp. Common Stock
AVR
$148M
| $11.9M | 0.33% |
+2,140,000
| New | +$11.9M |
|
56
EyePoint Pharmaceuticals
EYPT
$827M
| $11.5M | 0.32% |
1,537,274
+500,000
| +48% | +$3.73M |
|
57
Edwards Lifesciences
EW
$47.7B
| $10.7M | 0.3% |
+145,000
| New | +$10.7M |
|
|
58
Tarsus Pharmaceuticals
TARS
$2.44B
| $10.3M | 0.28% |
186,662
-1,109,754
| -86% | -$61.4M |
|
|
ADGM
59
Adagio Medical Holdings, Inc Common Stock
ADGM
$25.1M
| $10.3M | 0.28% |
9,812,419
| – | – |
|
60
Insmed
INSM
$30.3B
| $9.94M | 0.27% |
144,000
-36,000
| -20% | -$2.49M |
|
61
Crinetics Pharmaceuticals
CRNX
$3.26B
| $9.43M | 0.26% |
184,525
-540,173
| -75% | -$27.6M |
|
62
RAPT Therapeutics
RAPT
$187M
| $9.29M | 0.26% |
+735,000
| New | +$9.29M |
|
63
Ocular Therapeutix
OCUL
$2.25B
| $9.21M | 0.25% |
1,078,495
-2,245,973
| -68% | -$19.2M |
|
|
NARI
64
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $9.13M | 0.25% |
+178,797
| New | +$9.13M |
|
|
OKUR
65
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $8.64M | 0.24% |
+1,004,439
| New | +$8.64M |
|
66
Nurix Therapeutics
NRIX
$723M
| $6.23M | 0.17% |
+330,614
| New | +$6.23M |
|
|
ZBIO
67
Zenas BioPharma, Inc. Common Stock
ZBIO
$722M
| $6.09M | 0.17% |
744,035
-400,000
| -35% | -$3.28M |
|
68
iRhythm Technologies
IRTC
$5.67B
| $5.87M | 0.16% |
65,153
+42,562
| +188% | +$3.84M |
|
|
RAPP
69
Rapport Therapeutics
RAPP
$549M
| $5.53M | 0.15% |
311,551
-436,632
| -58% | -$7.75M |
|
|
BBOT
70
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$779M
| $5.25M | 0.14% |
500,000
| – | – |
|
71
Rocket Pharmaceuticals
RCKT
$358M
| $4.76M | 0.13% |
378,584
-553,267
| -59% | -$6.95M |
|
|
CBLL
72
CeriBell, Inc. Common Stock
CBLL
$419M
| $4.67M | 0.13% |
+180,546
| New | +$4.67M |
|
73
Veru
VERU
$48.5M
| $4.22M | 0.12% |
648,316
-80,000
| -11% | -$520K |
|
|
MREO
74
Mereo BioPharma
MREO
$275M
| $3.8M | 0.1% |
1,085,512
+269,790
| +33% | +$944K |
|
75
Perspective Therapeutics
CATX
$251M
| $3.8M | 0.1% |
+1,190,263
| New | +$3.8M |
|